Fjarde AP Fonden Fourth Swedish National Pension Fund Buys 49,900 Shares of Royalty Pharma PLC $RPRX

Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its position in Royalty Pharma PLC (NASDAQ:RPRX) by 42.2% in the first quarter, Holdings Channel reports. The firm owned 168,250 shares of the biopharmaceutical company’s stock after buying an additional 49,900 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Royalty Pharma were worth $8,071,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Barton Investment Management acquired a new stake in Royalty Pharma in the first quarter valued at approximately $905,000. Nomura Asset Management Co. Ltd. increased its position in shares of Royalty Pharma by 16.2% during the fourth quarter. Nomura Asset Management Co. Ltd. now owns 172,418 shares of the biopharmaceutical company’s stock worth $6,662,000 after purchasing an additional 24,048 shares in the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new position in shares of Royalty Pharma during the fourth quarter worth $4,923,000. Qsemble Capital Management LP purchased a new stake in shares of Royalty Pharma during the 4th quarter valued at $2,875,000. Finally, Regal Partners Ltd lifted its holdings in shares of Royalty Pharma by 6.7% during the 3rd quarter. Regal Partners Ltd now owns 1,435,126 shares of the biopharmaceutical company’s stock valued at $50,631,000 after purchasing an additional 89,930 shares during the last quarter. 54.35% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. UBS Group boosted their target price on Royalty Pharma from $51.00 to $57.00 and gave the stock a “buy” rating in a research note on Tuesday, April 21st. Weiss Ratings downgraded Royalty Pharma from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, May 15th. Wall Street Zen upgraded Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Morgan Stanley upped their price objective on shares of Royalty Pharma from $61.00 to $63.00 and gave the company an “overweight” rating in a report on Friday, April 10th. Finally, Citigroup increased their price objective on shares of Royalty Pharma from $50.00 to $66.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Seven research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $53.71.

Insider Buying and Selling at Royalty Pharma

In other Royalty Pharma news, Director Gregory Norden sold 3,045 shares of the company’s stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $53.00, for a total value of $161,385.00. Following the sale, the director directly owned 191,803 shares of the company’s stock, valued at approximately $10,165,559. This represents a 1.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Terrance P. Coyne sold 64,399 shares of the stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $53.98, for a total value of $3,476,258.02. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 427,800 shares of company stock worth $23,333,723. 18.84% of the stock is currently owned by company insiders.

Royalty Pharma Stock Performance

Royalty Pharma stock opened at $57.77 on Monday. The company has a quick ratio of 2.66, a current ratio of 2.66 and a debt-to-equity ratio of 0.86. Royalty Pharma PLC has a 52 week low of $34.08 and a 52 week high of $57.80. The company has a market capitalization of $33.27 billion, a price-to-earnings ratio of 39.30, a price-to-earnings-growth ratio of 1.59 and a beta of 0.43. The stock has a 50-day moving average price of $53.56 and a 200 day moving average price of $47.30.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.08. Royalty Pharma had a net margin of 33.88% and a return on equity of 29.25%. The company had revenue of $630.58 million for the quarter, compared to the consensus estimate of $881.69 million. Sell-side analysts anticipate that Royalty Pharma PLC will post 5.05 EPS for the current year.

Royalty Pharma Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th were issued a $0.235 dividend. This represents a $0.94 annualized dividend and a dividend yield of 1.6%. The ex-dividend date of this dividend was Friday, May 15th. Royalty Pharma’s dividend payout ratio is 63.95%.

Royalty Pharma Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.